Japanese bioventure Solasia Pharma K.K.'s Darvias (darinaparsin; SP-02) has received its first approval in Japan for the treatment of relapsed/refractory peripheral T-cell lymphoma (PTCL), marking the end of a decades-long journey to market for the organoarsenical molecule's original US inventor.
Although the reimbursement price under the country's national health insurance system following the 20 June approval has yet to be decided, Tokyo-based Solasia told Scrip that it has a plan to launch the product between June and December through local